FindTrial
Sign In

Investigation of vaginal probiotics reducing high risk HPV infection and the changes of vaginal microecology before and after treatment.

Investigation of vaginal probiotics reducing high risk HPV infection and the changes of vaginal microecology before and after treatment.

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100046239
Enrollment
Unknown
Registered
2021-05-12
Start date
2021-07-01
Completion date
Unknown
Last updated
2021-12-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

The high risk of cervical HPV infection

Interventions

Control group :No
Experimental group A:Interferon
Experimental group B:Interferon+vaginal viable lactobacillus crimp preparation

Sponsors

The First hospital of Nanchang
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 50 Years

Inclusion criteria

Inclusion criteria: 1. Informed consent; 2. Aged 20 to 50 years; 3. Sexual life history; 4. No drugs are used; 5. No sexual activity, no vaginal irrigation and drug application during the week before examination. Note: Patients receiving drug therapy were high-risk HPV positive patients

Exclusion criteria

Exclusion criteria: 1. Pregnant or lactating women and menopausal women; 2. Patients already suffering from cervical cancer or high-grade intraepithelial neoplasia; 3. Patients with other malignant tumors; 4. Complicated with serious heart, lung, kidney, liver dysfunction, metabolic diseases and immune deficiency; 5. People allergic to probiotics.

Design outcomes

Primary

MeasureTime frame
The clearance rate of high-risk human papillomavirus;Changes in vaginal flora;—

Countries

China

Contacts

Public ContactLiu Yujuan

The First Hospital of Nanchang (the Third Affiliated Hospital of Nanchang University)

liuyujuan123@163.com+86 13767156618

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026